Market Overview

The Global Market for Anticoagulants (2018-2025): Analysis by Drug Class, Route of Administration and Application -


The "Anticoagulants
Market by Drug Class, Route of Administration, and Application,
Pulmonary Embolism, and Others) - Global Opportunity Analysis and
Industry Forecast, 2018-2025"
report has been added to's

The global anticoagulants market was valued at $24,265 million in 2017,
and is expected to reach $43,427 million by 2025, growing at a CAGR of
7.5% from 2018 to 2025.

The global anticoagulants market is expected to grow at a significant
rate during the forecast period, owing to increasing prevalence of
venous thromboembolism (VTE) and cardiovascular disease across the
world, growing adoption of novel oral anticoagulants (NOACs), and
growing awareness of NOACs in developing regions.

Furthermore, increasing obese and geriatric population and growing
demand of novel therapeutics are anticipated to further influence the
market growth during the forecast period.

On the other side, higher price of NOACs and lack of antidots for NOACs
impede the market growth.

Profiles for:

Key Players

  • Aspen Holdings
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Daiichi Sankyo Company Ltd.
  • GlaxoSmithKline PLC
  • Johnson & Johnson (Janssen Pharmaceuticals, Inc.)
  • Pfizer Inc.
  • Portola Pharmaceuticals Inc.
  • Sanofi S.A.

Other Players

  • Armetheon Inc.
  • Astrazeneca
  • Celgene Corporation

Key Topics Covered

Chapter 1: Introduction

Chapter 2: Executive Summary

Chapter 3: Market Overview

Chapter 4: Anticoagulants Market, by Drug Class

Chapter 5: Anticoagulants Market, by Route of Administration

Chapter 6: Anticoagulants Market, by Application

Chapter 7: Anticoagulants Market by Region

Chapter 8: Company Profiles

For more information about this report visit

View Comments and Join the Discussion!